Antitubercular activity of 2-mercaptobenzothiazole derivatives targeting <i>Mycobacterium tuberculosis</i> type II NADH dehydrogenase-Reference-Cited by-同舟云学术

Antitubercular activity of 2-mercaptobenzothiazole derivatives targeting Mycobacterium tuberculosis type II NADH dehydrogenase

Published:2024 Issue:5 Volume:15 Page:1664-1674
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Saha Pallavi¹^ORCID,Sau Shashikanta²,Kalia Nitin Pal²^ORCID,Sharma Deepak K.¹^ORCID

Affiliation:

1. Department of Pharmaceutical Engg. and Tech, IIT-Banaras Hindu University, Varanasi, UP, 221005, India

2. Department of Pharmacology and Toxicology, NIPER-Hyderabad, Hyderabad, 500037, India

Abstract

Mycobacterium tuberculosis (Mtb) type II NADH dehydrogenase (NDH-2) transports electrons into the mycobacterial respiratory pathway at the cost of reduction of NADH to NAD+ and is an attractive drug target.

Funder

Science and Engineering Research Board

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/MD/D4MD00118D

Reference40 articles.

1. WHO , Global Tuberculosis Report Resume , 2023 , pp. 2–3 , accesed on 10 december 2023

2. Tuberculosis

3. Unravelling the flexibility of Mycobacterium tuberculosis: an escape way for the bacilli

4. Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts

5. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is "science" enough to tackle the epidemic?

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. P-glycoprotein inhibitors as an adjunct therapy for TB;Drug Discovery Today;2024-09